Explore Ultragenyx Pharmaceutical's Q1 2024 financial performance, strategic milestones, and expert insights from the latest earnings call.
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Comprehensive Analysis of Ultragenyx's Latest Financial Performance and Future Outlook